Prostate cancer: Bone density testing-essential or extraneous?
Nat Rev Urol., Dec (2012)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy.
N. Engl. J. Med., Dec (2012)
Advanced clinical States in prostate cancer.
Urol. Clin. North Am., Nov;39(4):561-71 (2012)
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
J. Urol., Jul;188(1):103-9 (2012)
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
J. Clin. Oncol., May;30(15):1864-70 (2012)
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
J. Clin. Oncol., Feb;30(5):507-12 (2012)
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Urology., May;77(5):1166-71 (2011)
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Clin Nucl Med., Mar;36(3):192-8 (2011)
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
J. Clin. Oncol., Sep;28(27):4247-54 (2010)
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
J. Clin. Oncol., Jun;28(16):2668-73 (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet., Apr;375(9724):1437-46 (2010)
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Clin. Cancer Res., Dec;15(23):7421-8 (2009)
Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor.
J. Clin. Oncol., Dec;27(34):e215-7 (2009)
Positron emission tomography imaging as a cancer biomarker.
Expert Rev. Mol. Diagn., Sep;7(5):659-72 (2007)
The origin of cancer.
Cancer Treat. Res., 122:1-22 (2004)
Genetic alterations in prostate cancer.
Clin Prostate Cancer., Mar;3(4):220-9 (2005)